About
I studied Medicine at Cambridge (1983-1989) before taking up clinical training posts in Internal Medicine (Nottingham, 1990-1992) and Haematology (Liverpool, 1992-2000), during which time I completed a PhD on p53 and drug resistance in chronic lymphocytic leukaemia (CLL). In 2000, I was appointed as Clinical Senior Lecturer in Haematology at the University of Liverpool, with subsequent promotion to Reader (2004) and Personal Chair (2006) and designation as the Ronald Finn Professor of Experimental Medicine (2013). I am also a Consultant in Haemato-Oncology (HO) at the Clatterbridge Cancer Centre (CCC), having previously been based at the Royal Liverpool University Hospital prior to transfer of the HO clinical service in 2017. Local leadership roles have included UoL Head of Department of Molecular and Clinical Cancer Medicine (2011-2020), Chair of the UoL Clinical Trials Oversight Committee (2018-2023), Director of the Liverpool Health Partners Cancer Programme (2019-2022), Director of the Liverpool Cancer Research Institute (2020-2022), and CCC Associate Medical Director for HO (2020). National Leadership roles have included Chair of the UK CLL Forum (2006-2012), Chair of the National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group (2012-2017), and Chair of the NCRI Lymphoma Clinical Studies Group (2017-2023). My current focus is on the UNCOVER health data research programme for blood cancer, the UK Blood Cancer Biobank as a driver/enabler of translational research in CLL and lymphoma, and the PETReA phase III clinical trial as a platform for follicular lymphoma research.